Hemorrhagic Fever

Dengue hemorrhagic fever is classified as a severe manifestation within the broader spectrum of symptomatic dengue virus infection, distinct from uncomplicated dengue fever ^[1][2][3]. The condition is fundamentally characterized by pathophysiological plasma leakage, which differentiates it from milder forms and underlies its potential progression to circulatory collapse ^[2]. As an arthropod-borne illness, it encompasses a range of clinical presentations that require careful diagnostic differentiation based on symptom severity and systemic involvement ^[1][4][3].

Symptomatic infection typically begins with acute-onset high fever accompanied by prominent myalgia, arthralgia, and cutaneous rash ^[1]. While most cases resolve as self-limited febrile illnesses, a subset progresses to severe disease marked by hemorrhagic episodes and signs of vascular compromise ^[1][2]. Hepatic involvement is frequently observed in severe presentations, with hepatocellular injury manifesting as hepatomegaly, jaundice, and elevated aminotransferase levels, occasionally culminating in acute liver failure ^[4].

Dengue hemorrhagic fever represents one of the most rapidly emerging infectious threats across tropical and subtropical zones globally, increasingly impacting both rural and urban populations due to multifactorial drivers including climatic shifts ^[4][3]. While the majority of viral infections remain asymptomatic, approximately twenty-five percent of infected individuals develop clinically apparent febrile illness, with severe manifestations developing in a minority of those cases ^[4]. Understanding the disseminated pattern and regional status of the virus remains essential for tracking its evolving geographic footprint ^[3].

The dengue virus operates as an arthropod-borne pathogen that cycles primarily between human hosts and Aedes aegypti mosquitoes ^[1]. Transmission occurs through established vector-mediated pathways that facilitate viral spread within endemic communities ^[1]. These human–vector–human dynamics sustain continuous circulation in regions where mosquito breeding habitats overlap with human settlement patterns ^[1].

Given the current absence of specific antiviral medications and widely licensed vaccines for any clinical stage of dengue, public health strategies prioritize active case monitoring and continuous vector surveillance ^[2]. Effective mitigation relies on implementing long-term control policies that reduce environmental reservoirs and limit human-mosquito contact ^[1][3]. Early identification of clinical warning signs before progression to critical complications remains a cornerstone of reducing overall disease burden ^[2].

1. 1Parveen S et al. Dengue hemorrhagic fever: a growing global menace. J Water Health. 2023 Nov. PMID: 38017595. doi: 10.2166/wh.2023.114.PubMed: https://pubmed.ncbi.nlm.nih.gov/38017595/
2. 2Wang WH et al. Dengue hemorrhagic fever - A systemic literature review of current perspectives on pathogenesis, prevention and control. J Microbiol Immunol Infect. 2020 Dec. PMID: 32265181. doi: 10.1016/j.jmii.2020.03.007.PubMed: https://pubmed.ncbi.nlm.nih.gov/32265181/
3. 3Khan MB et al. Dengue overview: An updated systemic review. J Infect Public Health. 2023 Oct. PMID: 37595484. doi: 10.1016/j.jiph.2023.08.001.PubMed: https://pubmed.ncbi.nlm.nih.gov/37595484/
4. 4Leowattana W et al. Dengue hemorrhagic fever and the liver. World J Hepatol. 2021 Dec 27. PMID: 35070001. doi: 10.4254/wjh.v13.i12.1968.PubMed: https://pubmed.ncbi.nlm.nih.gov/35070001/